Cardiovascular Diseases Clinical Trial
Official title:
Enhanced Continuity of Pharmacy Care for Cardiovascular or Pulmonary Diseases
This study will test whether enhanced continuity of pharmacy care that includes increased communication between inpatient and outpatient settings will improve the appropriateness of medication therapy and reduce the number of serious adverse drug events, hospitalizations and unscheduled office visits in vulnerable patients with cardiovascular disease, pulmonary disease or diabetes.
Drugs used to treat cardiovascular and lung diseases are the most frequent cause of
hospitalizations and emergency department visits related to inadequate therapy or ADEs. ADEs
occur in 25% of patients who are able to walk and may cause up to 17% of hospital admissions
among the elderly. A lack of communication and coordination between the hospital setting and
the patient's own community setting, upon patient discharge, may contribute to the high
number of ADEs. By expanding the role of pharmacists and encouraging communication between
hospitals and pharmacists, the number of ADEs may be reduced. There have been a few small
studies that have examined the way patient information is transferred between hospital and
community pharmacists, but these studies did not involve the patients' primary care
physicians nor did they fully evaluate the effect of communication between hospital and
community pharmacists. The purpose of this study is to evaluate the effectiveness of
providing a pharmacist case manager to hospitalized patients with cardiovascular or lung
disease at reducing the number of ADEs, re-hospitalizations, and unscheduled medical visits.
This study will enroll individuals with certain conditions or diseases who are admitted to
the hospital. Participants will be randomly assigned to either a control group, a minimal
treatment group, or an enhanced treatment group. Participants in the minimal and enhanced
treatment groups will meet with a pharmacist case manager while in the hospital to conduct a
medication history review. The case manager will also meet with participants at the time of
hospital discharge and provide them with a discharge summary and educational materials.
Additionally, for participants in the enhanced treatment group, the case manager will do the
following: transfer the discharge summary data to the participant's community physician and
pharmacist; call the participant 3 to 5 days following discharge from the hospital and as
needed thereafter to resolve medication problems; and communicate with and make
recommendations to the participant's community physician and pharmacist. All participants
will meet with a study research nurse immediately after study entry to complete
questionnaires. Study nurses will also call all participants 30 and 90 days following
hospital discharge to collect adverse event information. Surveys will be completed by each
participant's pharmacist and primary care physician 90 days following the participant's
discharge from the hospital.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|